EPHA2 and medulloblastoma: Supporting this, microarray data from 29 medulloblastoma samples revealed subgroup-specific expression patterns: EphA2 is enriched in non-SHH tumors (WHO groups 3 and 4) but absent in SHH subtypes, suggesting a potential role in the pathobiology of more aggressive medulloblastoma variants (Morrison et al., 2013).